image: MicroCT images and 3D renderings of tumors in the livers of rats two weeks after receiving either saline (left), ethanol (middle), or LATTE (right). This material relates to a paper that appeared in the Jan. 20, 2021, issue of <i>Science Translational Medicine</i>, published by AAAS. The paper, by H. Albadawi at Mayo Clinic in Phoenix, AZ; and colleagues was titled, "Percutaneous liquid ablation agent for tumor treatment and drug delivery." view more
Credit: [Credit: H. Albadawi <i>et al., Science Translational Medicine</i> (2021)]
A liquid formulation can kill swathes of liver cancer cells and potentiate chemotherapy treatments, according to a study conducted in mice, rabbits, pigs and human tumor samples. The liquid could offer clinicians a safer and cheaper "bridge" to keep tumors in check in patients waiting for life-saving liver transplants. Chemotherapy remains the treatment of choice for patients with hepatocellular carcinoma (HCC), but these drugs have not made a major impact on five-year patient survival rates, which remain dismally low at around 9%. However, research has shown that liver transplantation can drastically improve outcomes in patients, raising 5-year survival rates to approximately 80%. Securing a liver transplant is therefore a major priority for clinicians and patients with early-stage disease, but organs are often difficult to find. In the meantime, clinicians keep tumors in check with local techniques such as thermal ablation - a procedure that vaporizes cancer cells with heat - but these approaches are resource-intensive, cannot be applied to all tumors, and can damage surrounding tissues. Hassan Albadawi and colleagues designed an alternative ablation technique based on an ionic liquid named LATTE, which can deliver both ablating agents and chemotherapy drugs directly into tumors. The team found that injections of LATTE shrank tumors either alone or in combination with the chemotherapy drug doxorubicin in rat and rabbit models of HCC, and rapidly killed cancer cells in 12 resected human tumors. "We anticipate that the safety profile of LATTE, its low cost, its simplicity of use, and the flexibility to repeat the procedure will make this [technique] appealing to physicians," the authors say.
###
Journal
Science Translational Medicine